Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Aurélie Swalduz, Michèle Beau‐Faller, David Planchard, Julien Mazieres, Sophie Bayle-Bleuez, D. Debieuvre, Vincent Fallet, Margaux Geier, Alexis B. Cortot, S. Couraud, Catherine Daniel, Charlotte Domblides, Éric Pichon, Elizabeth Fabre, Sébastien Larivé, U. Lerolle, Pascale Tomasini, Marie Wislez, Pascale Missy, Franck Morin, Virginie Westeel, J.B. Auliac
Topics & Concepts
MedicineDabrafenibTrametinibOncologyInternal medicineCohortLung cancerCancerMetastatic melanomaGeneticsMAPK/ERK pathwayVemurafenibKinaseBiologyLung Cancer Treatments and MutationsMelanoma and MAPK PathwaysSynthesis and biological activity